Meloxicam: Difference between revisions
| [unchecked revision] | [checked revision] |
MDElliottMD (talk | contribs) Create stub for Meloxicam (linked from Category:NSAIDs Members section) |
MDElliottMD (talk | contribs) parser-claude: Meloxicam MedTemplate refill, Top 300 stub upgrade |
||
| Line 1: | Line 1: | ||
{{MedTemplate | {{MedTemplate | ||
| generic = Meloxicam | | generic = Meloxicam | ||
| brand | | brand = Mobic, Vivlodex (lower-dose capsules), Anjeso (IV) | ||
| classes = NSAID | | structure = | ||
| | | classes = [[:Category:NSAIDs|Non-steroidal anti-inflammatory (NSAID, preferential COX-2)]], [[:Category:Analgesics|Analgesic]] | ||
| uses = <vote slug="osteoarthritis-use">Osteoarthritis (FDA)</vote>, <vote slug="rheumatoid-arthritis-use">Rheumatoid arthritis (FDA, adult)</vote>, <vote slug="juvenile-ra-use">Juvenile rheumatoid arthritis (FDA, ≥2 years)</vote>, <vote slug="ankylosing-spondylitis-use">Ankylosing spondylitis (FDA)</vote>, <vote slug="acute-pain-meloxicam-use">Acute pain (off-label oral; Anjeso IV formulation)</vote> | |||
| starting_dose = 7.5 mg PO once daily; titrate to 15 mg daily if needed. Vivlodex 5 mg PO once daily, max 10 mg | |||
| preparations = Tablets 7.5, 15 mg (Mobic); capsules 5, 10 mg (Vivlodex); oral suspension 7.5 mg/5 mL; injection 30 mg/mL (Anjeso) | |||
| fda_max = 15 mg/day (oral); 30 mg IV once daily (Anjeso) | |||
| pill_id = | |||
| routes = Oral, intravenous | |||
| onset = Analgesic effect within hours; full anti-inflammatory effect over 1-2 weeks | |||
| duration = 24 hours (once-daily dosing supported by long half-life) | |||
| halflife = 15-20 hours<ref name="mobic-label">FDA Prescribing Information, Mobic (meloxicam), Boehringer Ingelheim, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020938s022lbl.pdf</ref> | |||
| bioavailability = ~89% (oral)<ref name="mobic-label" /> | |||
| pregnancy = Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)<ref name="mobic-label" /> | |||
| legal = [[USLegal:Prescription only|Rx-only]] in US | |||
| mechanism = <vote slug="meloxicam-mech-claim">Preferential COX-2 over COX-1 inhibitor (approximately 3:1 selectivity at therapeutic doses), giving somewhat less GI mucosal injury than non-selective NSAIDs but not the COX-2 specificity of celecoxib. Anti-inflammatory and analgesic effect derives from reduced prostaglandin synthesis; the cardiovascular and renal class effects of NSAIDs apply, with the standard FDA Boxed Warning for cardiovascular thrombotic events and gastrointestinal bleeding.</vote> Once-daily dosing is a clinical advantage over short-half-life NSAIDs<ref name="mobic-label" />. | |||
}} | }} | ||
== References == | |||
<references /> | |||
[[Category:NSAIDs]] | |||
[[Category:Analgesics]] | |||
Latest revision as of 06:27, 23 May 2026
Meloxicam
Mobic, Vivlodex (lower-dose capsules), Anjeso (IV)
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Osteoarthritis (FDA)0, Rheumatoid arthritis (FDA, adult)0, Juvenile rheumatoid arthritis (FDA, ≥2 years)0, Ankylosing spondylitis (FDA)0, Acute pain (off-label oral; Anjeso IV formulation)0
Pharmacy
Starting dose
7.5 mg PO once daily; titrate to 15 mg daily if needed. Vivlodex 5 mg PO once daily, max 10 mg
Preparations
Tablets 7.5, 15 mg (Mobic); capsules 5, 10 mg (Vivlodex); oral suspension 7.5 mg/5 mL; injection 30 mg/mL (Anjeso)
US FDA Max
15 mg/day (oral); 30 mg IV once daily (Anjeso)
Pharmacology
Routes
Oral, intravenous
Onset
Analgesic effect within hours; full anti-inflammatory effect over 1-2 weeks
Duration
24 hours (once-daily dosing supported by long half-life)
Half-life
15-20 hours[1]
Bioavailability
~89% (oral)[1]
Pregnancy
Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)[1]
Legal status
Rx-only in US
Purported mechanism
Preferential COX-2 over COX-1 inhibitor (approximately 3:1 selectivity at therapeutic doses), giving somewhat less GI mucosal injury than non-selective NSAIDs but not the COX-2 specificity of celecoxib. Anti-inflammatory and analgesic effect derives from reduced prostaglandin synthesis; the cardiovascular and renal class effects of NSAIDs apply, with the standard FDA Boxed Warning for cardiovascular thrombotic events and gastrointestinal bleeding.0 Once-daily dosing is a clinical advantage over short-half-life NSAIDs[1].
References
- ↑ 1.0 1.1 1.2 1.3 FDA Prescribing Information, Mobic (meloxicam), Boehringer Ingelheim, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020938s022lbl.pdf